A Zika Vaccine Generated Using the Chimeric Insect-Specific Binjari Virus Platform Protects against Fetal Brain Infection in Pregnant Mice.
Jessamine E HazlewoodDaniel J RawleBing TangKexin YanLaura J VetEri NakayamaJody Hobson-PetersRoy A HallAndreas SuhrbierPublished in: Vaccines (2020)
Zika virus (ZIKV) is the etiological agent of congenital Zika syndrome (CZS), a spectrum of birth defects that can lead to life-long disabilities. A range of vaccines are in development with the target population including pregnant women and women of child-bearing age. Using a recently described chimeric flavivirus vaccine technology based on the novel insect-specific Binjari virus (BinJV), we generated a ZIKV vaccine (BinJ/ZIKA-prME) and illustrate herein its ability to protect against fetal brain infection. Female IFNAR-/- mice were vaccinated once with unadjuvanted BinJ/ZIKA-prME, were mated, and at embryonic day 12.5 were challenged with ZIKVPRVABC59. No infectious ZIKV was detected in maternal blood, placenta, or fetal heads in BinJ/ZIKA-prME-vaccinated mice. A similar result was obtained when the more sensitive qRT PCR methodology was used to measure the viral RNA. BinJ/ZIKA-prME vaccination also did not result in antibody-dependent enhancement of dengue virus infection or disease. BinJ/ZIKA-prME thus emerges as a potential vaccine candidate for the prevention of CSZ.
Keyphrases
- zika virus
- aedes aegypti
- dengue virus
- pregnant women
- high fat diet induced
- pregnancy outcomes
- cell therapy
- white matter
- mental health
- stem cells
- multiple sclerosis
- metabolic syndrome
- resting state
- case report
- body mass index
- polycystic ovary syndrome
- risk assessment
- insulin resistance
- physical activity
- mesenchymal stem cells
- climate change
- brain injury
- breast cancer risk